Interview: Steve Bates – CEO, BioIndustry Association (BIA), UK
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
Address: 7th Floor, Southside
105 Victoria Street
London
SW1E 6QT
UK
Tel: +44 (0)20 7630 2180
Web: http://www.bioindustry.org/home/
The UK BioIndustry Association, the BIA, is the trade association for innovative enterprises involved in UK bioscience. Members include start-up, emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.
The BIA works to further the interests of members and the industry – nationally and internationally. Our heritage of innovation, enterprise and success dates back to our founding over 20 years ago.
Influencing Progress
Bioscience is a national priority for the UK. The BIA works to encourage and promote a financially sound and thriving bioscience sector within the UK economy.
Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, to help enable our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
Lobbying is a core BIA strength. We provide a strong, unified, relentless voice for bioscience to stakeholders — including government, politicians, the media and patient advocate groups — to address the critical issues our members face and to push for progress. We educate policy makers about the needs of our members and advocate for legislation and policies essential to their growth and success.
Enabling Connections
Collaboration is key to moving bioscience forward. To support and enhance collaboration, the BIA brings together organisations from across the life sciences industry. This includes service providers, valued not only for the vital functions they serve in the sector, but also for their business acumen, expert guidance and industry connections.
The BIA hosts events throughout the year where members and others from the sector can learn, discuss, debate and network.
BIA Advisory Committee meetings connect peer groups to engage in debate and develop solutions to shared issues and challenges.
The BIA also keeps members connected and updated via regular communications. In addition, the BIA provides a host of other business development and business support services to enhance the value of membership. We facilitate introductions to other BIA members, provide meeting spaces at our central London office, offer member-only discounts to BIA and selected third-party events and also with suppliers.
In fulfilling its mission, the BIA aims to:
1 Offer a wide range of member services and benefits to the satisfaction of the membership
2 Represent the needs of the industry and its members on important issues
3 Promote best practice within the industry
4 Facilitate industry growth and maturity, positioning the UK as a leading world player in bioscience
5 Campaign for the best possible environment for innovative bioscience research
6 Communicate the benefits of innovative bioscience technologies
7 Maintain its role as the Association of choice for membership representation and communication on innovative bioscience issues
The BIA operates an active public affairs programme, a well-developed conference and and seminar programme, trade missions, regular publications for internal and external audiences, plus a series of committees whose interests range from regulatory affairs and intellectual property to personnel and finance and taxation. Networking and technology-transfer opportunities for members and others with an interest in the sector ensure that every avenue is explored in the support of UK bioscience.
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease.…
After spending five years heading market access globally, Lars Bruening returned to a country manager role in the UK; he shares with us his thoughts on Brexit while also highlighting…
Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s…
Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to…
One notable quirk of the British life sciences ecosystem is the importance of its not-for-profit sector. Indeed, in 2017, UK charities poured GBP 1.6 billion (USD 2.1 billion) into medical…
Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid…
Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and…
The new AI tech from Google’s DeepMind can diagnose over 50 retinal diseases with more accuracy than your optometrist. Research conducted by Nature Medicine found that a ground-breaking artificial intelligence system developed…
Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James…
Richard Erwin, general manager of Roche Products Ltd in the UK, speaks out about the challenges facing the company, from market access to uptake of innovation, to collaborating with diverse…
With a strong historic footprint in Edinburgh, Canon Medical Systems has based one of its global R&D centres in Scotland from where it develops software for its devices. Ken Sutherland,…
After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR…
See our Cookie Privacy Policy Here